New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:24 EDTABBV, IDIX, MRKAbbVie shares defended at BMO Capital
After Abbvie's (ABBV) stock fell following Merck's (MRK) acquisition of Idenix (IDIX), BMO Capital still believes that the size and durability of the HCV market and Abbvie's franchise are unappreciated. The firm sees Merck as a significant competitor in HCV, but adds that the potential of the assets it acquired from Idenix is "uncertain and somewhat risky." BMO Capital continues to identify AbbVie as a top pick.
News For ABBV;IDIX;MRK From The Last 14 Days
Check below for free stories on ABBV;IDIX;MRK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 21, 2014
10:27 EDTABBVUBS pharma and federal affairs analysts hold an analyst/industry conference call
Subscribe for More Information
08:01 EDTABBVAbbVie acquisition positive, says Argus
Subscribe for More Information
07:59 EDTABBVShire downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Shire (SHPG) on Friday to Market Perform citing the takeover by AbbVie (ABBV) as it does not expect competitive bids to emerge.
07:21 EDTMRKGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
06:43 EDTMRK, ABBVGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
06:10 EDTABBVStocks with implied volatility movement; ABBV JOY
Subscribe for More Information
July 18, 2014
18:04 EDTABBVAbbVie purchase of Shire worth the premium, Barron's reports
Subscribe for More Information
16:47 EDTABBVMarket ends week higher as earnings, M&A offset geopolitical tensions
Subscribe for More Information
13:46 EDTABBVAbbVie price target raised to $85 from $71 at Jefferies
Subscribe for More Information
10:34 EDTABBVShire downgraded to Neutral from Overweight at Piper Jaffray
Shire (SHPG) is being acquired by AbbVie (ABBV).
10:30 EDTABBVAbbVie says can't back out of Shire deal based on tax law change, Bloomberg says
Subscribe for More Information
09:29 EDTABBVAbbVie, Shire says merger should help in enhanced buyback and dividend programs
Subscribe for More Information
05:17 EDTABBVAbbVie, Shire agree on merger worth GBP32B pounds
The boards of AbbVie (ABBV) and Shire (SHPG) announced that they have reached agreement on the terms of a recommended combination of Shire with AbbVie. Under the terms of the Merger, Shire shareholders will be entitled to receive per share GBP 24.44 in cash and 0.8960 new AbbVie shares. Immediately following the transaction, Shire shareholders are expected to hold new AbbVie Shares representing approximately 25% of the issued share capital of new AbbVie. AbbVie expects the transaction to be accretive to adjusted earnings per share in the first year following completion, growing to above $1.00 per share by 2020, with "material ongoing financial and operating benefits." The AbbVie board also expects the transaction to reduce New AbbVie's effective tax rate to approximately 13% by 2016. The Shire board said it "considers the terms of the Transaction to be fair and reasonable." In order to undertake the transaction, AbbVie has formed a new company, New AbbVie, which is incorporated in Jersey, Shire's current place of incorporation. Following completion of the Transaction, New AbbVie will become the holding company of the Shire Group and the AbbVie Group. It is intended that the New AbbVie Shares will be listed on the New York Stock Exchange.
05:12 EDTABBVAbbVie to acquire Shire for 52.48 pounds per share in cash, stock
Subscribe for More Information
July 17, 2014
12:56 EDTABBVAbbVie set to announce GBP 31B deal to buy Shire, FT says
Subscribe for More Information
12:54 EDTABBVAbbVie set to announce GBP 31B deal to buy Shire, FT says
Subscribe for More Information
11:12 EDTIDIXOptions with decreasing implied volatility
Subscribe for More Information
05:53 EDTABBVStocks with implied volatility movement; HLF ABBV
Stocks with implied volatility movement; Herbalife (HLF) 52, AbbVie (ABBV) 30 according to iVolatility.
July 16, 2014
07:59 EDTABBVTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
06:26 EDTMRKBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use